Internal Server Error

NeuraLace Medical - About the company

NeuraLace Medical is a seed company based in San Diego (United States), founded in 2016 by Shiv Shukla. It operates as a Non-invasive neuromodulation for chronic neuropathic pain relief and improved patient outcomes. NeuraLace Medical has raised $5.85M in funding from FusionX Ventures. The company has 3003 active competitors, including 937 funded and 706 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Illumina and Karyopharm.

Company Details

Non-invasive neuromodulation for chronic neuropathic pain relief and improved patient outcomes. They are focused on revolutionizing chronic pain management through its electroceutical platform, offering a non-invasive alternative to traditional methods. Their Axon Therapy mPNS technology uses magnetic peripheral nerve stimulation to recondition the central nervous system, providing long-term relief from post-trauma and post-surgical neuropathic pain. This innovative approach minimizes dependence on opioids and other medications, improving patients' quality of life. The company's technology is FDA-cleared and supported by clinical trial results, demonstrating significant effects in pain reduction. They are dedicated to freeing the world from chronic neuropathic suffering through advanced neuromodulation technology.
Social
X
Phone Number
+1 **********
Key Metrics
Founded Year
2016
Location
San Diego, United States
Stage
Seed
Total Funding
$5.85M in 2 rounds
Latest Funding Round
Ranked
Employee Count
22 as on Mar 31, 2026
Similar Companies
Sign up to download NeuraLace Medical's company profile

NeuraLace Medical's funding and investors

NeuraLace Medical has raised a total funding of $5.85M over 2 rounds. Its first funding round was on Mar 15, 2017. Its latest funding round was a Seed round on Jun 19, 2019 for $*****. 4 investors participated in its latest round. NeuraLace Medical has 8 institutional investors.

Here is the list of recent funding rounds of NeuraLace Medical:
Date of Funding
Funding Amount
Round Name
Post-Money Valuation
Revenue Multiple
Lead Investors
Other Investors
Jun 19, 2019
1725407
Seed
1316020
2740382
1192360
3194878
Mar 15, 2017
2289035
Seed
8537873
7319672
lockAccess funding benchmarks and valuations. Sign up today!

NeuraLace Medical's founders and board of directors

Founder? Claim Profile
The founders of NeuraLace Medical is Shiv Shukla.
Here are the details of NeuraLace Medical's key team members:

NeuraLace Medical's employee count trend

NeuraLace Medical has 22 employees as of Mar 26. Here is NeuraLace Medical's employee count trend over the years:
Employee count trend for NeuraLace Medical
lockUncover NeuraLace Medical's growth story! Sign up today!
chrome_extension_cta_illustration
Access Tracxn on any website
Our Google Chrome extension lets you view company details while browsing their websites
Install Tracxn Extension

NeuraLace Medical's Competitors and alternates

Top competitors of NeuraLace Medical include Jazz Pharmaceuticals, Illumina and Karyopharm. Here is the list of Top 10 competitors of NeuraLace Medical, ranked by Tracxn score:
Rank
Company Details
Short Description
Total Funding
Investors
Tracxn Score
1st
Logo for Jazz Pharmaceuticals
Jazz Pharmaceuticals
2003, Dublin (Ireland), Public
Developer of novel biopharmaceutical medicines for unmet medical needs
$265M
81/100
2nd
Logo for Illumina
Illumina
1993, San Diego (United States), Public
Developer of technologies for analysis of genetic variation and function
$28M
81/100
3rd
Logo for Karyopharm
Karyopharm
2008, Natick (United States), Public
Developer of small molecule drugs for the treatment of cancer and inflammatory disease
$98.4M
75/100
4th
Logo for argenx
argenx
2008, Ghent (Belgium), Public
Developer of antibody-based drugs to treat autoimmune diseases and cancer
$61.9M
74/100
5th
Logo for C4 Therapeutics
C4 Therapeutics
2016, Cambridge (United States), Public
Developer of small molecule drugs for treating cancer
$223M
74/100
6th
Logo for Syndax
Syndax
2005, Waltham (United States), Public
Developer of targeted therapies for the treatment of cancer
$198M
74/100
7th
Logo for Alector
Alector
2013, San Francisco (United States), Public
Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders
$215M
74/100
8th
Logo for Erasca
Erasca
2018, San Diego (United States), Public
Developer of small molecule based therapeutics for cancer
$300M
72/100
9th
Logo for Landis+Gyr
Landis+Gyr
1896, Zug (Switzerland), Public
Provider of end-to-end energy management solutions
$1.03B
72/100
10th
Logo for Juno Therapeutics
Juno Therapeutics
2013, Seattle (United States), Acquired
CAR T-Cell and T-Cell Receptor-based immunotherapies for the treatment of cancer.
$317M
71/100
1098th
Logo for NeuraLace Medical
NeuraLace Medical
2016, San Diego (United States), Seed
Non-invasive neuromodulation for chronic neuropathic pain relief and improved patient outcomes
$5.85M
40/100
lockGet insights and benchmarks for competitors of 2M+ companies! Sign up today!
Looking for more details on NeuraLace Medical's competitors? Click here to see the top ones

NeuraLace Medical's Investments and acquisitions

NeuraLace Medical has made no investments or acquisitions yet.

Reports related to NeuraLace Medical

Here is the latest report on NeuraLace Medical's sector:

News related to NeuraLace Medical

lockFilter this list
NeuraLace Medical Closes $3 Million Seed RoundSan Diego Business JournalJun 16, 2019NeuraLace Medical
lockGet curated news about company updates, funding rounds, M&A deals and others. Sign up today!

FAQs about NeuraLace Medical

Explore our recently published companies
  • Saga - London based, 2017 founded, Series A company
  • Sitel - Gurugram based, 1985 founded, Acquired company
  • Zapi - Singapore based, 2025 founded, Unfunded company
  • CorpChamber - Jakarta based, 2023 founded, Unfunded company
  • Oxynum - Paris based, 2012 founded, Unfunded company
  • WAVEE - Tokyo based, 2022 founded, Unfunded company
Tracxn powers 1,000+ customers across 30+ countries
Accel PartnersPartechIN-Q-TEL - USFujitsuTenityStanford